IGF-1 LR3 Results and Timelines: What Studies Report

Searches for IGF-1 LR3 "results" and "how long it takes to work" assume there is a published timeline to report. In the verified literature summarised here, there is not. The studies that exist used animal models, measured biochemical and tissue-level endpoints, and in several cases reported that the expected effect did not occur. This page describes what was measured, in which model, over what duration, and what researchers reported — nothing more.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision. Nothing here describes a protocol, a schedule, or an expected outcome for any individual.

What IGF-1 LR3 is, in the terms the literature uses

Long R3 IGF-1 (LR3 IGF-1) is an engineered analogue of insulin-like growth factor 1. It carries an extended N-terminal peptide and an amino-acid substitution at position 3, modifications intended to reduce binding to IGF binding proteins so that more of the molecule remains unbound in circulation or in tissue fluid. A 2023 study in Applied Microbiology and Biotechnology described recombinant expression of both native IGF-1 and LR3 IGF-1 as xylanase fusion constructs in Pichia pastoris, a production-focused paper concerned with expression yield and downstream processing rather than physiological effect (PMID 37261455).

That production paper is worth naming explicitly because it illustrates how much of the LR3 literature sits upstream of any outcome question. A substantial share of published work on this analogue concerns how to make it, characterise it, and verify its identity — not what it does over weeks in a living subject.

Studies that measured outcomes: model, duration, and what researchers reported

Late-gestation growth-restricted fetal sheep

The most direct "does it produce growth" question in the verified set was addressed in a 2025 paper in the American Journal of Physiology — Endocrinology and Metabolism. Researchers administered IGF-1 LR3 to late-gestation growth-restricted fetal sheep and assessed whether growth was promoted. As the title states, the study reported that IGF-1 LR3 did not promote growth in that model (PMID 39679943).

This is a negative finding in a model chosen because growth was already impaired — that is, a setting where a growth-promoting effect would have been most detectable. The study is informative precisely because it looked for the outcome most people are searching for and reported its absence in that species and developmental window (PMID 39679943).

Acute infusion and insulin secretion in fetal sheep

A 2023 paper in the Journal of Developmental Origins of Health and Disease examined a different endpoint over a much shorter window. Researchers reported that glucose-stimulated insulin secretion was attenuated during an acute IGF-1 LR3 infusion into fetal sheep, but that this attenuation did not persist in isolated islets studied afterwards (PMID 37114757).

Two features of that result matter for anyone reading about timelines. First, the effect appeared acutely — during the infusion itself — rather than accumulating over days. Second, it was not carried forward by the tissue: once islets were removed and studied in isolation, the change was no longer evident, which the authors framed as the effect being a function of the ongoing systemic exposure rather than a durable change to the islet (PMID 37114757).

Intranasal delivery in a transgenic Alzheimer's mouse model

A 2025 study in the Journal of Alzheimer's Disease used a different route and a different endpoint set. Researchers treated male 5XFAD mice intranasally with long R3 IGF-1 and reported that treatment promoted amyloid plaque remodeling in the cerebral cortex but failed to preserve cognitive function (PMID 39610283).

This is a dissociation worth stating plainly: a measurable tissue-level change occurred without the functional benefit the tissue change was hypothesised to support. Readers looking for "results" often assume that any detectable biological change implies a downstream benefit. This study reported the opposite pattern in that model (PMID 39610283).

Summary table of verified findings

Why the literature does not support a timeline

Three structural features of this evidence base make "how long until results" unanswerable from published work.

• The models are not humans. Fetal sheep and 5XFAD transgenic mice were selected to answer specific developmental and neuropathological questions (PMID 39679943, PMID 39610283). Growth physiology, IGF binding protein profiles, clearance and receptor distribution differ substantially between these models and adult humans.
• The endpoints are not the ones people search for. The verified studies measured fetal growth, insulin secretion, amyloid plaque morphology and cognition. None measured adult body composition, strength, recovery or appearance.
• Several primary outcomes were negative. Growth was not promoted in growth-restricted fetal sheep, and cognition was not preserved in treated mice, despite a detectable plaque change (PMID 39679943, PMID 39610283). A negative primary outcome cannot generate a timeline for a positive one.

Where a time-course statement can be made at all, it is narrow: the insulin-secretion change was described as occurring during an acute infusion and as not persisting once tissue was isolated (PMID 37114757). That is a statement about one endpoint in one species, not a general onset window.

Reading effect sizes and "before and after" claims critically

Anecdotal accounts circulating online are not part of this evidence base and are not summarised here. When evaluating any claim about this analogue, the questions that the verified literature makes salient are:

1. Which species and which developmental stage? Fetal physiology, as studied in the sheep papers, is not adult physiology (PMID 39679943).
2. Which route of administration? The mouse study used intranasal delivery specifically to target the central nervous system (PMID 39610283); the sheep work used systemic infusion (PMID 37114757).
3. Was the measured change a mechanism marker or a functional outcome? Plaque remodeling was a tissue marker; cognition was the functional outcome, and the two diverged (PMID 39610283).
4. Did the change persist after exposure ended? In the islet study it did not (PMID 37114757).

Metabolic observations: What Studies Report

The verified set contains one physiological observation directly relevant to safety-adjacent discussion. Researchers reported that glucose-stimulated insulin secretion was attenuated during acute IGF-1 LR3 infusion into fetal sheep, an effect that was not reproduced in isolated islets afterwards (PMID 37114757). IGF-1 and its analogues interact with glucose regulation, and this study documented one such interaction in a specific model.

Beyond that, the verified papers in this set did not report an adverse-event profile in humans. No human safety data, dose-limiting toxicity, or tolerability information appears in the four studies cited here. The absence of reported harms in a small preclinical literature is not evidence of safety; it reflects that the relevant studies were not designed or powered to characterise safety in people.

Regulatory context

IGF-1 LR3 is not an approved medicine. Material sold under that name is typically labelled for research use only, and research-use-only labelling means a substance has not been evaluated or authorised for administration to humans. The verified literature reflects this status: it consists of an expression-system production study and animal work, not registration trials (PMID 37261455).

What the evidence base would need to answer the timeline question

For a defensible statement about onset or duration of effect in people, the literature would need controlled human trials with pre-specified endpoints, defined exposure periods, and reported effect sizes with confidence intervals. None of the four verified papers provides that. Until such work exists, statements about how quickly IGF-1 LR3 "works" are extrapolations from animal endpoints — several of which were negative — rather than summaries of measured human outcomes (PMID 39679943, PMID 39610283).

Individual outcomes are not predictable from this literature. The studies described above measured different endpoints in different species using different routes, and the results diverged even within single experiments. No inference about an individual's response, its magnitude, or its timing follows from them.

References

• Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris (Applied Microbiology and Biotechnology, 2023)
• IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep (American Journal of Physiology. Endocrinology and Metabolism, 2025)
• Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice (Journal of Alzheimer's Disease, 2025)
• Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets (Journal of Developmental Origins of Health and Disease, 2023)